|
1
|
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391:1023–1075. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, et al: Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial. JAMA. 330:2064–2074. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liang F: The KEYNOTE-061 trial. Lancet. 393(1098)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, et al: CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. 36:2836–2844. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
An M, Mehta A, Min BH, Heo YJ, Wright SJ, Parikh M, Bi L, Lee H, Kim TJ, Lee SY, et al: Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer. Cancer Discov. 14:766–785. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yanez P, Wyrwicz LS, Shen L, Ostapenko Y, et al: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 402:2197–2208. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, et al: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 24:483–495. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, et al: Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA. 326:916–925. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, et al: Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 31:4438–4444. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, Koukouma A, Chau I and Cunningham D: Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer. 47:1146–1151. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, et al: Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): A randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 6:1015–1024. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang X, Wang Y, Xiang X, Pan H, Zhang J, Chen X, Ba Y, Jieer Y, He Y, Yin X, et al: Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial. Journal of Clinical Oncology, 2024ASCO (abstract 4012), 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4012.
|
|
17
|
Tang XH, Wu XL, Gan XJ, Wang YD, Jia FZ, Wang YX, Zhang Y, Gao XY and Li ZY: Using normalized carcinoembryonic antigen and carbohydrate antigen 19 to predict and monitor the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer. Int J Mol Sci. 24(12192)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kawahara K, Makino H, Kametaka H, Hoshino I, Fukada T, Seike K, Kawasaki Y and Otsuka M: Outcomes of surgical resection for gastric cancer liver metastases: A retrospective analysis. World J Surg Oncol. 18(41)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nam DH, Lee YK, Park JC, Lee H, Shin SK, Lee SK, Lee YC, Cheong JH, Hyung WJ, Noh SH and Kim CB: Prognostic value of early postoperative tumor marker response in gastric cancer. Ann Surg Oncol. 20:3905–3911. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Torun BC, Sobutay E, Akbulut OE, Saglam S, Yilmaz S, Yonemura Y and Canbay E: Important predictive factors for the prognosis of patients with peritoneal metastasis of gastric cancer. Ann Surg Oncol. 31:5975–5983. 2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen X, Zhang H, Wang M, Liu H, Hu Y, Lin T, Chen H, Zhao M, Chen T, Li G, et al: relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front Immunol. 13(783695)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, et al: Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 33:929–938. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, et al: Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study. Clin Cancer Res. 25:515–523. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020.PubMed/NCBI View Article : Google Scholar
|
